Peroxisome proliferator-activated receptor translational research and clinical experience.
about
Fibroblast growth factor 21: from pharmacology to physiologyIdentification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13.Pharmacophore-driven identification of PPARγ agonists from natural sources.In Silico Identification of Potent PPAR-γ Agonists from Traditional Chinese Medicine: A Bioactivity Prediction, Virtual Screening, and Molecular Dynamics Study.Effects of Endogenous PPAR Agonist Nitro-Oleic Acid on Metabolic Syndrome in Obese Zucker Rats.Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine.Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humansImproving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal musclePioglitazone attenuates vascular fibrosis in spontaneously hypertensive ratsPPARγ isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation.Common genetic variants in peroxisome proliferator-activated receptor-γ (PPARG) and type 2 diabetes risk among Women's Health Initiative postmenopausal women.Lipoprotein metabolism in nonalcoholic fatty liver diseaseN-3 Polyunsaturated Fatty Acids Improve Liver Lipid Oxidation-Related Enzyme Levels and Increased the Peroxisome Proliferator-Activated Receptor α Expression Level in Mice Subjected to Hemorrhagic Shock/Resuscitation.History of current non-insulin medications for diabetes mellitus.Adiponectin in insulin resistance: lessons from translational research.Emerging options in the treatment of dyslipidemias: a bright future?Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury.PPARγ agonist-induced alterations in Δ6-desaturase and stearoyl-CoA desaturase 1: Role of MEK/ERK1/2 pathway.
P2860
Q24658126-8DE7E70D-700C-43B6-836C-5C7263F23729Q30990011-5B3E32D0-541E-4F91-B8D3-821BEA43EC45Q33744181-1B3648C5-14C2-42DA-9661-FC27B92DE9CDQ33757779-6A03E70C-D4EF-4054-8626-C0D94DC0347EQ34021895-4EB45B46-E11C-4DD3-A648-59B86FB94244Q34316470-E93E9014-9041-4094-8FD8-CE8B491FF91CQ35019725-B9DF13A0-0ED4-4AA8-BAF7-D9268CD046C1Q35774443-4F451B4A-3133-41F2-A079-8D11B45F83D8Q35884929-D0543671-4C9F-4871-89A8-821FDD48B1E9Q36211459-7671E521-C32D-4F08-85F1-4F86C6D4309EQ36663024-9756E204-28F1-46B8-A3EF-0AD90603024CQ36682138-33561C1F-DC36-44A4-84EA-F1197202AFA3Q36846386-63D5DA3C-22F6-4D5C-9368-1B6DD71D533CQ37021310-EDDF715A-1FA5-4F6F-BC55-221E92F15DFFQ37474736-A3F6148A-5BA4-48D4-B3A7-93371862006EQ37842462-2CEAC485-F68B-4DD1-8F65-F7FF48E53724Q37899155-90A38EB7-8D22-489D-9C4C-36AC82383BC5Q39152313-72AED3F8-9199-4E78-B0C1-E3A574D7B542
P2860
Peroxisome proliferator-activated receptor translational research and clinical experience.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Peroxisome proliferator-activa ...... earch and clinical experience.
@en
Peroxisome proliferator-activa ...... earch and clinical experience.
@nl
type
label
Peroxisome proliferator-activa ...... earch and clinical experience.
@en
Peroxisome proliferator-activa ...... earch and clinical experience.
@nl
prefLabel
Peroxisome proliferator-activa ...... earch and clinical experience.
@en
Peroxisome proliferator-activa ...... earch and clinical experience.
@nl
P356
P1476
Peroxisome proliferator-activa ...... earch and clinical experience.
@en
P2093
Wayman Wendell Cheatham
P304
P356
10.3945/AJCN.2009.28449D
P407
P577
2009-11-18T00:00:00Z